Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.
<h4>Background/aims</h4>Non-alcoholic fatty liver disease (NAFLD) represents a significant public health issue. Identifying patients with simple steatosis from those with non-alcoholic steatohepatitis (NASH) is crucial since NASH is correlated with increased morbidity and mortality. Seru...
Guardado en:
Autores principales: | Atul Goyale, Anjly Jain, Colette Smith, Margarita Papatheodoridi, Marta Guerrero Misas, Davide Roccarina, Laura Iogna Prat, Dimitri P Mikhailidis, Devaki Nair, Emmanuel Tsochatzis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/329e810f046c49ec9cdd03bbadbcecc5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Correlation between Non-Alcoholic Fatty Liver Disease (NAFLD) fibrosis score (NFS) with Left Ventricular Mass Index (LVMI) in patients with NAFLD
por: Tri Ferry Rachmatullah, et al.
Publicado: (2021) -
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
por: Lucía Barbier-Torres, et al.
Publicado: (2020) -
Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
por: Sue Shea, et al.
Publicado: (2021) -
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C
por: Pegah Golabi, et al.
Publicado: (2022) -
Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Daniela Maria Tanase, et al.
Publicado: (2021)